New drug tested to halt teen vision loss from rare eye disease

NCT ID NCT05244304

Completed Disease control Sponsor: Belite Bio, Inc Source: ClinicalTrials.gov ↗

Summary

This study tested whether a drug called tinlarebant could slow the progression of Stargardt disease, a rare genetic condition that causes vision loss in young people. About 104 teenagers and young adults took either the drug or a placebo for up to two years. The main goal was to see if the drug could slow the growth of damaged areas in the back of the eye.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Belite Study Site

Palo Alto, California, 94303, United States
Belite Study Site

Minneapolis, Minnesota, 55435, United States
Belite Study Site

Salt Lake City, Utah, 84132, United States
Belite Study Site

Westmead, New South Wales, Australia
Belite Study Site

East Melbourne, Victoria, Australia
Belite Study Site

South Brisbane, Australia
Belite Study Site

Ghent, Belgium
Belite Study Site

Beijing, China
Belite Study Site

Shanghai, China
Belite Study Site

Paris, France
Belite Study Site

Bonn, Germany
Belite Study Site

Tübingen, Germany
Belite Study Site

Kowloon, Hong Kong
Belite Study Site

Nijmegen, Netherlands
Belite Study Site

Basel, Switzerland
Belite Study Site

Taipei, Taiwan
Belite Study Site

Taoyuan, Taiwan
Belite Study Site

London, United Kingdom
Belite Study Site

Southampton, United Kingdom

Conditions

Explore the condition pages connected to this study.

STARGARDT DISEASE 1